.
MergerLinks Header Logo

New Deal


Announced

Completed

QIAGEN completed the acquisition of an 80.1% stake in NeuMoDx Molecular for $248m.

Synopsis

QIAGEN, a provider of Sample to Insight solutions, completed the acquisition of an 80.1% stake in NeuMoDx Molecular, a diagnostics instruments company, from private equity firms Baird Capital Partners, Venture Investors, Arboretum Ventures and Pfizer Venture for $248m. “NeuMoDx’s automated molecular testing platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics assays, including laboratory-developed tests. NeuMoDx has built an unparalleled platform that has demonstrated superior value during the coronavirus pandemic. This will expand QIAGEN’s portfolio of automated testing solutions and provide another driver for future growth,” Thierry Bernard, QIAGEN CEO.

Show Details & Financials

Market Context

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US